Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma by Tan, Justin L. et al.
Stress from nucleotide depletion activates the transcriptional 
regulator HEXIM1 to suppress melanoma
Justin L. Tan1,2, Rachel D. Fogley1,2, Ryan A. Flynn3, Julien Ablain1,2, Song Yang1,2, 
Violaine Saint-André4, Zi Peng Fan4, Brian T. Do3, Alvaro C. Laga5, Koh Fujinaga6, Cristina 
Santoriello1,2, Celeste B. Greer7, Yoon Jung Kim8, John G. Clohessy9,10, Anne Bothmer9, 
Nicole Pandell10, Serine Avagyan1,2, John E. Brogie11, Ellen van Rooijen1,2, Elliott J. 
Hagedorn1,2, Ng Shyh-Chang12, Richard M. White13, David H. Price11, Pier Paolo Pandolfi9, 
B. Matija Peterlin6, Yi Zhou1,2, Tae Hoon Kim8, John M. Asara14, Howard Y. Chang3, Richard 
A. Young4, and Leonard I. Zon1,2,*
1Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/
Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, 
Boston, MA 02115, USA.
2Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 
02138, USA.
3Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA 
94305, USA.
4Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute 
of Technology, Cambridge, MA 02142, USA.
5Department of Pathology, Brigham & Women's Hospital, Boston, MA 02215, USA.
6Departments of Medicine, Microbiology and Immunology, Rosalind Russell Medical Research 
Center, University of California, San Francisco, CA 94143, USA.
7Department of Pharmacology, Yale University, School of Medicine, New Haven, CT 06520, USA.
8Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX 75080, 
USA.
*Corresponding Author: Leonard I. Zon, Boston Children's Hospital / HHMI, Karp Research Building, Room 7211, 300 Longwood 
Ave, Boston, MA 02115, 617-919-2069, zon@enders.tch.harvard.edu. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Author Contributions:
Conceptualization, J.L.T. and L.I.Z.; Supervision, J.L.T., R.M.W., D.H.P., P.P.P., B.M.P., T.H.K., J.M.A., H.Y.C., R.A.Y. and L.I.Z.; 
Funding Acquisition & Resources, L.I.Z., D.H.P., P.P.P., B.M.P., Y.Z., T.H.K., J.M.A., H.Y.C. and R.A.Y.; Writing – Original Draft, 
J.L.T.; Writing – Review & Editing, J.L.T. and L.I.Z.; Methodology, J.L.T. and L.I.Z.; Investigation, J.L.T., R.D.F., R.A.F., J.A., S.Y., 
V.S., Z.P.F., B.T.D., A.C.L., K.F., C.S., C.B.G., Y.J.K., J.G.C., A.B., N.P., S.A., J.E.B., E.v.R., E.J.H. and N.S.; Formal Analysis, 
J.L.T., R.A.Y., S.Y. and C.B.G.
eTOC Blurb:
Tan et al. demonstrate that the gene HEXIM1 is a tumor suppressor in melanoma that responds to nucleotide stress by inhibiting 
transcription elongation of tumorigenic genes and stabilizing mRNA transcripts of other tumor suppressor genes. These results suggest 
an important paradigm for targeting melanoma through metabolic stress-induced transcription regulation.
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Summary
Studying cancer metabolism gives insight into tumorigenic survival mechanisms and 
susceptibilities. In melanoma, we identify HEXIM1, a transcription elongation regulator, as a 
melanoma tumor suppressor that responds to nucleotide stress. HEXIM1 expression is low in 
melanoma. Its overexpression in a zebrafish melanoma model suppresses cancer formation while 
its inactivation accelerates tumor onset in vivo. Knockdown of HEXIM1 rescues zebrafish neural 
crest defects and human melanoma proliferation defects that arise from nucleotide depletion. 
Under nucleotide stress, HEXIM1 is induced to form an inhibitory complex with P-TEFb, the 
kinase that initiates transcription elongation, to inhibit elongation at tumorigenic genes. The 
resulting alteration in gene expression also causes anti-tumorigenic RNAs to bind to and be 
stabilized by HEXIM1. HEXIM1 plays an important role in inhibiting cancer cell-specific gene 
transcription while also facilitating anti-cancer gene expression. Our study reveals an important 
role for HEXIM1 in coupling nucleotide metabolism with transcriptional regulation in melanoma.
Graphical Abstract
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Introduction
The ability of cancer cells to alter metabolism to enhance survival and adapt to the 
microenvironment has been studied to understand tumorigenic mechanisms that can be 
therapeutically targeted. Nucleotide metabolism is dysregulated in cancer. Imbalances in 
nucleotide pools alter mutation rates (Meuth, 1989; Weinberg et al., 1981). Dysregulation of 
nucleotide biosynthesis precursors glycine and glutamine in tumorigenesis invoke changes 
in nucleotide metabolism (Liu et al., 2012; Zhang et al., 2012). Genetic mutations with 
altered nucleotide metabolism cause chromosomal instability (Chabosseau et al., 2011; 
Chang et al., 2013). Our previous work found that inhibition of de novo pyrimidine 
biosynthesis enzyme dihydro-orotate dehydrogenase (DHODH), by drug leflunomide (lef), 
ablates zebrafish neural crest and suppresses melanoma through an unclear transcription 
elongation mechanism (White et al., 2011).
Control of the elongation phase of RNA polymerase II (RNA Pol II) transcription regulates 
gene expression during differentiation (Guo and Price, 2013). After initiation, RNA Pol II 
becomes paused at the promoter by negative transcription elongation factors such as DSIF 
and NELF (Muse et al., 2007; Rahl et al., 2010). Release of these promoter proximal paused 
polymerases into productive elongation requires positive transcription elongation factor b (P-
TEFb) (Marshall et al., 1996). P-TEFb, comprising cyclin-dependent kinase 9 (CDK9) and 
either cyclin T1 or T2 (CCNT1/2), phosphorylates RNA Pol II (Marshall et al., 1996), DSIF 
(Yamada et al., 2006) and NELF (Fujinaga et al., 2004). This releases NELF from the 
elongation complex and converts DSIF into a positive factor (Fujinaga et al., 2004; Yamada 
et al., 2006), resulting in productive elongation (Rahl et al., 2010).
The 7SK snRNP critically regulates transcription elongation by sequestering and 
inactivating P-TEFb (Peterlin et al., 2012). Negative regulation of P-TEFb by HEXIM1 in 
the 7SK snRNP is essential for regulating gene expression. HEXIM1 binds to 7SK RNA and 
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sequesters P-TEFb in an inactive state (Yik et al., 2003). 7SK snRNP components MEPCE 
(bcdin3) (Jeronimo et al., 2007) and LARP7 (He et al., 2008) maintain 7SK stability. 
Regulated release of P-TEFb from the 7SK snRNP is important for rapid gene induction for 
metazoan development. 7SK snRNP disruption leads to developmental abnormalities in 
zebrafish (Barboric et al., 2009) and humans (Alazami et al., 2012).
To determine how nucleotide metabolism affects transcription in tumors, we examined the 
relevance of negative regulators of transcription elongation in cancer and found that 
HEXIM1 features significantly in melanoma. Our analysis revealed that HEXIM1 mRNA 
and protein levels are low in melanoma. In vivo studies demonstrate that HEXIM1 functions 
as a melanoma suppressor: its overexpression suppresses tumor onset, while its inactivation 
accelerates tumorigenesis. Pyrimidine nucleotide depletion induces SP1-mediated HEXIM1 
upregulation to suppress melanocyte and neural crest formation in vivo. Under nucleotide 
stress, HEXIM1 forms an inhibitory complex with P-TEFb, inhibiting productive elongation 
at neural crest-associated and tumorigenic genes. The alteration in gene expression causes 
anti-tumorigenic transcripts to bind to and become stabilized by HEXIM1. HEXIM1 
induction by nucleotide stress facilitates a gene expression switch, inhibiting tumorigenic 
gene transcription while favoring anti-tumorigenic gene transcription. The ability of 
HEXIM1 to couple nucleotide stress with an anti-melanoma transcriptional response is an 
important mechanism in tumor metabolism.
Results
HEXIM1 expression is low in melanoma
We evaluated the role of candidate transcription elongation regulators in Oncomine (Rhodes 
et al., 2004) and only HEXIM1 expression was significantly altered in melanoma (data not 
shown). We analyzed two human melanoma microarray datasets for HEXIM1 expression 
(Lin et al., 2008; Talantov et al., 2005). Talantov et al. studied gene expression from primary 
melanoma and benign skin nevi, while Lin et al. examined gene expression in melanoma 
short-term cultures and cell lines. HEXIM1 is downregulated by at least 2-fold in 78% of 
nevi compared to normal skin controls (Figures 1A and S1A). Comparing melanoma and 
skin, HEXIM1 is downregulated in 100% of melanoma cases by at least 2-fold (Figures 1A 
and S1A). In short-term cultures and cell lines vs. normal melanocyte lines, 44% of 
melanoma cases have HEXIM1 downregulated by at least 2-fold (Figures 1B and S1A). 
Other 7SK snRNP members were not significantly downregulated (Figure S1B). HEXIM1 is 
likely downregulated in melanoma.
To assess HEXIM1 protein levels, we performed immunohistochemistry on human 
melanoma tissue microarrays. We scored them by the H-score method on a scale of 0 to 300 
(McClelland et al., 1990). 66% of nevi and 72% of human melanoma samples showed low 
H-scores of < 100, corresponding to low HEXIM1 protein levels (Figures 1C and S1C). 6% 
of nevi and 13% of melanoma showed high HEXIM1 levels with H-scores of > 200 (Figures 
S1C and S1D). 100% of normal epidermal samples scored high for HEXIM1 expression, 
with 94% of samples possessing H-scores of > 200 (Figures S1C and S1D). As melanoma is 
derived from melanocytes, we examined normal epidermal sections co-stained for HEXIM1 
and MART1, a melanocyte specific cell surface antigen (Kawakami et al., 1994). 
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Melanocytes co-express high levels of both MART1 and HEXIM1, meaning that HEXIM1 
protein levels are high in normal melanocytes compared to nevi and melanoma (Figure S1E). 
These results suggest that HEXIM1 protein is downregulated in melanoma.
There are no significant mutations in the HEXIM1 gene across tumor databases (data not 
shown), suggesting that in melanoma, epigenetic silencing might cause HEXIM1 
downregulation. We examined DNA methylation of the HEXIM1 locus using MethHC 
(Huang et al., 2015) to analyze melanoma methylation data from The Cancer Genome Atlas 
(TCGA). The HEXIM1 promoter is hypermethylated in tumor samples, suggesting that 
hypermethylation downregulates HEXIM1 (Figure 1D). To functionally test if the HEXIM1 
promoter is methylated in melanoma, we treated the human A375 melanoma cell line with 
5-azacytidine, a DNA methyltransferase (DNMT) inhibitor which removes methylation on 
DNA (Creusot et al., 1982). We observed a dose-dependent upregulation of HEXIM1 
transcripts (Figure 1E) and reduced cell viability (Figure 1F) with DNMT inhibition. 
Together, the expression patterns and epigenetic silencing by DNA methylation suggest that 
HEXIM1 is a tumor suppressor that is downregulated in melanoma.
HEXIM1 overexpression suppresses melanoma onset while its inactivation accelerates 
melanoma in vivo
To investigate the in vivo action of HEXIM1 on melanoma, we overexpressed human 
HEXIM1 and zebrafish hexim1 in the MiniCoopR zebrafish assay system (Ceol et al., 
2011). Compared to the EGFP background control and the SETDB1 positive control, which 
accelerates tumor onset, both human HEXIM1 and fish hexim1 suppress melanoma onset 
(Figures 2A and 2B). 80% of HEXIM1/hexim1 fish remain tumor-free at the 25-week 
endpoint, while 30% of EGFP and 10% of SETDB1 fish are tumor-free.
We investigated if HEXIM1 suppression of tumorigenesis is dependent on its P-TEFb 
sequestration function. HEXIM1/P-TEFb interaction is modulated by mutating HEXIM1 
amino acid residues at S268, T270, T276 and S278, located at the P-TEFb binding domain 
(Contreras et al., 2007). Mutating these sites to aspartic acid generates HEXIM1-4D, which 
ablates P-TEFb binding. Mutating these sites to alanine generates HEXIM1-4A, which 
efficiently sequesters P-TEFb. Overexpressing HEXIM1-4A suppresses tumors to a similar 
extent as HEXIM1 and hexim1 (Figure 2C). Overexpressing HEXIM1-4D did not suppress 
tumors and tumorigenesis continued at a similar rate to EGFP (Figure 2C). We validated 
MiniCoopR transgenic construct expression by sequencing and western blots (Figures S2A, 
S2B and S2C).
We investigated the effects of HEXIM1 overexpression in melanocytes during development. 
We outcrossed HEXIM1, HEXIM1-4A and -4D MiniCoopR transgenic fish to the 
Tg(mitfa:BRAFV600E);p53−/−;mitfa−/− parental strain and examined melanocytes at 2 days 
post fertilization (dpf), using a Tu wildtype strain incross as control (Figure S2D). The 
outcrosses for the HEXIM1 and HEXIM1-4D strains produced offspring with an embryonic 
decrease in melanocytes, similar to DHODH inhibition effects (White et al., 2011). This 
melanocyte reduction did not occur for the EGFP or HEXIM1-4D strains. These studies 
show that the capacity of HEXIM1 to sequester P-TEFb is required for its function in tumor 
suppression and development.
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To analyze the effect of HEXIM1 inactivation in vivo, we employed a CRISPR/Cas9 
knockout of hexim1 in our zebrafish melanoma model. Under control of the MiniCoopR 
vector, we expressed hexim1 and p53 control guide RNAs, and Cas9 in a melanocyte-
specific fashion (Ablain et al., 2015) to examine tumor onset. Since the 
Tg(mitfa:BRAFV600E);p53−/−;mitfa−/− fish have non-functional p53, the p53 CRISPR 
controls for random targeting events. Mutation of the hexim1 gene was confirmed by a T7E1 
enzymatic genotyping assay and western blot showed lower hexim1 protein levels (Figures 
S2E and S2F). Reduced hexim1 expression due to heterozygous inactivation resulted in 
accelerated tumor onset compared to the p53 control (Figure 2D), consistent with HEXIM1 
functioning as a tumor suppressor.
We examined the tumor suppressive ability of HEXIM1 in a mouse xenograft model with a 
Tet-On HEXIM1-inducible A375 melanoma cell line (A375-HEXIM1). HEXIM1 induction 
with a doxycycline diet significantly reduced tumor growth rates compared to uninduced 
mice (Figure 2E and S2G), complementing our fish data that HEXIM1 is a melanoma 
suppressor.
Knockdown of HEXIM1 rescues neural crest and melanoma phenotypes associated with 
nucleotide stress
DHODH inhibition by lef ablates crestin (neural crest marker) and mitfa (master regulator of 
melanocyte fate) gene expression in developing zebrafish embryos (White et al., 2011). 
Hexim1 morpholino knockdown partially rescues crestin and mitfa expression in lef-treated 
zebrafish embryos (Figure 3A). Melanocytes are partially rescued (Figures 3B and 3C). 
Overexpressing human HEXIM1, via mRNA injection, with zebrafish hexim1 knockdown 
ablated the rescue. We validated hexim1 protein knockdown via western blot (Figure S3A). 
Hexim1 is ubiquitously expressed in early zebrafish development (Figures S3B, S3C and 
S3D). Knockdown of 7SK snRNP members larp7 and mepce recapitulated the rescue of 
melanocytic gene expression and melanocytes seen in hexim1 knockdown (Figures S3E and 
S3F). We observed melanocyte reduction in our HEXIM1 overexpressing zebrafish embryos 
(Figure S2D) similar to the lef embryonic phenotype. However, this is only a partial 
phenocopy of lef since crestin expression is unchanged (data not shown), possibly because 
HEXIM1 is specifically overexpressed in melanocytes under the mitfa promoter and the 
early neural crest cells affected by lef are still present in the transgenic embryos. Hexim1 
plays a role in neural crest in vivo effects caused by nucleotide stress.
DHODH inhibition causes growth arrest in the human A375 melanoma cell line (White et 
al., 2011). We performed pooled siRNA knockdown of HEXIM1 on A375 cells treated with 
A771726 and showed a partial rescue of the growth arrest phenotype (Figure 3D). A 
combined HEXIM1 and HEXIM2 knockdown marginally improved rescue while applying a 
non-targeting siRNA pool or GAPDH knockdown did not rescue (Figure 3D). Knockdowns 
were validated by RT-PCR (Figure S3G). These results suggest that HEXIM1 plays an 
important role in the transcriptional response to nucleotide stress in the neural crest lineage 
and melanoma.
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HEXIM1 is upregulated in response to nucleotide stress in melanoma
Metabolite profiling of A375 cells with metabolized lef, A771726, revealed that that 
pyrimidine biosynthesis and RNA transcription associated metabolites are primarily 
dysregulated (Figure S4A, Tables S1A and S1C). Metabolites upstream of DHODH are 
upregulated while metabolites downstream of DHODH are downregulated (Figures S4B and 
S4C). Changes are limited to pyrimidine intermediates before 48 hrs, after which secondary 
effects, such as purine metabolite changes, are observed (Figures S4A and S4C, Tables S1A 
and S1B). This highlights the specificity of DHODH inhibitors to pyrimidine biosynthesis.
To examine the effect of pyrimidine stress on HEXIM1 expression, zebrafish embryos and 
human A375 cells were treated with lef and A771726 respectively. HEXIM1 is upregulated 
with drug treatment in both systems in a dose-dependent manner by mRNA and protein 
levels (Figures 4A, 4B, 4C and 4D). We tested A771726 in our A375 HEXIM1-luciferase 
reporter line (Liu et al., 2014). A771726 increased HEXIM1 expression over time, similar to 
positive control hexamethylene bis-acetamide (HMBA) that upregulates HEXIM1 (Figure 
4E). HEXIM1 is upregulated after 48 hrs of drug treatment (Figure 4F) when pyrimidine 
nucleotides are significantly depleted (Figure S4C), and when growth arrest becomes 
significant (Figure 4G). Increased HEXIM1 expression induced by nucleotide stress can be 
rescued by adding pyrimidine nucleotides to drug-treated cells (Figure 4H). Adding 
nucleotides alone does not alter HEXIM1 expression (Figure 4H), suggesting that the role of 
HEXIM1 in transcriptional regulation is prominent in times of starvation and not nucleotide 
excess. Nucleotide starvation activates HEXIM1 with a corresponding decrease in cell 
proliferation.
HEXIM1 is upregulated by SP1 under nucleotide stress
We asked which transcription factor is responsible for HEXIM1 nucleotide stress 
upregulation by examining the ENCODE transcription factor ChIP-seq database (ENCODE 
Project Consortium, 2012) and selecting eight candidate transcription factors that 
significantly bind the HEXIM1 promoter. We screened these factors by siRNA knockdown 
to determine which one promotes HEXIM1 upregulation under nucleotide stress (Figure 
S5A). Knockdown was validated by RT-PCR (Figure S5B). SP1 knockdown significantly 
blocked HEXIM1 upregulation by A771726 treatment (Figures 5A and S5A). SP1 is a stress 
response factor (Ryu et al., 2003) and its knockdown partially rescues lef-induced growth 
arrest similar to HEXIM1 knockdown (Figure 5B). The HEXIM1 minimal promoter element 
used in the luciferase reporter assay in Figure 4E contains an SP1 binding element (Liu et 
al., 2014). ChIP-seq experiments demonstrate that SP1 binding is increased at many loci 
under nucleotide stress, where some genes are activated while others are repressed by RNA-
seq (data not shown). The HEXIM1 promoter is one region where SP1 binding is increased 
(Figure 5C) with an associated increase in HEXIM1 expression. These data establish a role 
for SP1 in the upregulation of HEXIM1 expression under nucleotide stress conditions.
HEXIM1 induction sequesters P-TEFb away from gene promoters
We investigated if HEXIM1 chromatin occupancy is affected by nucleotide stress by 
performing ChIP-seq for CDK9 and HEXIM1 in A375 cells treated with A771726 for 48 
hrs. We chose the 48 hr time point since HEXIM1 protein levels are significantly 
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upregulated (Figure 4F) with no induction of apoptosis (data not shown). It takes 24 hrs for 
lef to downregulate pyrimidines (Figure S4C), after which HEXIM1 is induced. RNA Pol II 
ChIP-seq and meta-gene analysis were performed on the same batch of cells to show that 
drug treatment did not affect immunoprecipitation efficiency (Figure S6A).
Meta-gene analysis demonstrates that CDK9 and HEXIM1 are localized at gene promoters 
(Figures 6A and 6B). ChIP-seq region plots for CDK9 and HEXIM1 binding throughout the 
genome, based on either CDK9 or HEXIM1 binding regions in the DMSO control, show co-
binding of HEXIM1 with CDK9 at the same regions (Figure 6C). We confirmed this co-
binding by performing ChIP-reChIP for HEXIM1 and CDK9. ChIP-reChIP region and 
meta-gene plots demonstrate that HEXIM1 and CDK9 indeed bind at identical chromatin 
regions (Figures S6B and S6C).
A771726 treatment reduces both CDK9 and HEXIM1 occupancy at the promoters (Figures 
6A and 6B). This reduction could be due to increased HEXIM1 sequestration of P-TEFb, 
where coimmunoprecipitation of HEXIM1 demonstrates that more CDK9 is being 
incorporated into the 7SK snRNP inhibitory complex with drug (Figure S6D). HEXIM1 
binding to P-TEFb is crucial for its in vivo tumor suppression activity and developmental 
effects (Figures 1H and S2D), which could account for the anti-proliferative effect that 
A771726 has on melanoma. These data suggest that HEXIM1 poises P-TEFb at gene 
promoters for a rapid release to the transcriptional machinery when required. Upon 
nucleotide stress, HEXIM1 is induced to sequester PTEFb to decrease productive 
elongation.
HEXIM1 induction reduces productive elongation at neural crest and tumorigenic genes
To examine the transcriptional effects of HEXIM1 sequestration of P-TEFb under nucleotide 
stress, we performed Global Run-On sequencing (GRO-seq) on A375 cells treated with lef 
or A771726 at the same time point as our ChIP-seq experiments. Genes that were considered 
expressed in the DMSO condition, with a traveling ratio (TR) cutoff of less than 7.5 (White 
et al., 2011), were used in the GRO-seq analysis for DMSO, lef and A771726 conditions. 
TR is a measure of RNA Pol II transcription along a gene in which read density at the 
promoter is divided by read density along the gene body (Rahl et al., 2010; Zeitlinger et al., 
2007). A higher TR corresponds to a decrease in productive elongation. RNA Pol II 
occupancy at the promoters and gene bodies is plotted for short-listed gene loci in all three 
conditions (Figure S6E). Overall TRs calculated from Figure S6E show a significant 
increase in TR for both lef and A771726 treatment (Figure 6D). Gene meta-analysis shows 
that RNA Pol II density is lower in the gene body with nucleotide stress (Figure 6E). RNA 
Pol II promoter density remains largely unchanged (Figure 6E), indicating that productive 
elongation is reduced with little effect on Pol II promoter proximal pausing. Example tracks 
of unaffected housekeeping gene β-Actin (ACTB) and affected melanoma-associated 
transcription factor HMGA2 (Raskin et al., 2013) are shown (Figure S6F). GRO-seq 
suggests that nucleotide stress reduces productive elongation in melanoma.
To assess HEXIM1's role in the reduction of productive elongation, we examined Serine-2 
phosphorylation (Ser2p) of the RNA Pol II C-terminal domain in A375 cells treated with 
A771726 and with HEXIM1 pooled knockdown. The transition into productive elongation 
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mediated by P-TEFb leads to increased Ser2p (Adelman and Lis, 2012). In cells with non-
targeting siRNA, Ser2p is decreased by 40% with increased HEXIM1 levels (Figure S6G). 
We expect this decrease in Ser2p since GRO-seq demonstrates a reduction in productive 
elongation at actively transcribed genes. Reduced Ser2p is rescued by HEXIM1 knockdown 
(Figure S6G). Nucleotide stress also causes a moderate transcription initiation defect, 
evident from the decrease in initiation marker Serine-5 phosphorylation (Ser5p) only 
partially rescued by HEXIM1 knockdown (Figure S6G). We induced HEXIM1 in the A375-
HEXIM1 cell line and observed a 40% decrease in Ser2p similar to A771726 treatment of 
endogenous A375 cells (Figure S6H). Ser5p is not significantly affected with HEXIM1 
overexpression (Figure S6H). RNA-seq on this HEXIM1 overexpressing line showed a trend 
of gene expression downregulation (Figure S6I). Gene expression was quantified by number 
of fragments per kilobase of transcript per million mapped reads (FPKM), with a cut-off of 
FPKM > 1 for expressed genes. We curated genes lists for significantly downregulated genes 
(defined as having an FPKM value of > 1 in the uninduced condition, with a corresponding 
decrease in FPKM upon HEXIM1 induction by > 1.5 fold) in the HEXIM1 overexpression 
RNA-seq (Table S2A) and genes with significant reduction in elongation (fold change in TR 
> 1.3, drug vs. DMSO) in the GRO-seq experiments (Figure 6F). We observed 692 genes 
that have decreased expression and elongation (Figure S6J). These results suggest that 
nucleotide stress induces HEXIM1 to reduce Ser2p and RNA Pol II mediated transcription 
elongation.
To examine how nucleotide stress-induced elongation inhibition suppresses melanoma, we 
performed Ingenuity Pathway Analysis (IPA) on the overlapping 2,003 GRO-seq genes with 
significant reduction in elongation (Figure 6F, Table S2B). Genes involved in gene 
expression, cell proliferation and cell death are enriched (Table S2C). We also performed 
IPA on a 137-gene list, obtained from overlapping the GRO-seq list with our previously 
published RNA Pol II ChIP-seq list (Figure S6K, Table S2D), which showed enrichment in 
cell cycle and proliferation pathways (Table S2E). A list of 368 neural crest associated genes 
was generated based on literature (Table S2F) and compared to GRO-seq elongation-
inhibited genes in Figure 6F. 33 neural crest associated genes, including known melanoma 
oncogenes, have significantly reduced elongation by GRO-seq (Table S2G). Through 
transcription factor motif analysis, MYC target genes were preferentially elongation-
inhibited (Figure S6L), as reported in our previous study (White et al., 2011). These data 
suggest that nucleotide stress induces HEXIM1 to suppress melanoma by reducing 
productive elongation at genes associated with melanoma progression.
HEXIM1 binds anti-tumorigenic transcripts under nucleotide stress
To survey global HEXIM1 RNA targets and determine if nucleotide stress causes changes in 
these RNA interactions, we performed FAST-iCLIP (Flynn et al., 2015) on HEXIM1 with 
A771726 treatment in A375 cells (Figure S7A). The proportion of 7SK bound to HEXIM1 
did not change significantly with drug (data not shown). We detected significant changes in 
mRNA transcripts bound to HEXIM1 (Figure 7A). Transcripts from 2012 genes were 
prominently bound by HEXIM1 at steady state. Upon nucleotide stress induction, 1063 
transcripts were no longer detected while 875 new gene transcripts were bound (Figure 7A). 
We observed 232 transcripts with increased binding, while 299 transcripts had decreased 
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binding (Figure 7A). Example transcripts of CDKN1A and PTEN are increasingly bound by 
HEXIM1 under nucleotide stress, while there is no change for CCNT2 transcripts (Figure 
7B). HEXIM1 RNA binding changes dynamically on specific gene transcripts although 
others remain unaffected.
To discern the biological consequence of altered HEXIM1 binding of mRNAs, we 
performed RNA-seq on A375 cells at various A771726-treatment time points as well as a 
DMSO-control 72 hr treatment to compare the changes in gene expression with the 
transcripts differentially bound by iCLIP. We found a positive correlation between 
transcripts that are upregulated by nucleotide stress in RNA-seq and transcripts bound more 
strongly by HEXIM1 under nucleotide stress (Figure S7B and Table S3). When comparing 
these transcripts to a list of GRO-seq genes that had increased transcriptional activity (TR 
fold change < 0.7) upon nucleotide stress, 116 genes, such as CDKN1A, were 
transcriptionally activated and increasingly bound by HEXIM1 (Figure S7C). Knockdown of 
HEXIM1 and HEXIM2 partially rescued the increased expression of these transcripts that 
were increasingly bound by HEXIM1 under nucleotide stress, such as CDKN1A and PTEN 
(Figure 7C). We detected genes such as CCNT2 that were bound by HEXIM1 and did not 
show any significant binding change under nucleotide stress (Figure 7B). These genes were 
not upregulated in RNA-seq and knockdown of HEXIM1 and HEXIM2 did not alter their 
expression (Figure 7C). This suggests that HEXIM1 differential binding stabilizes 
upregulated mRNAs to maintain their levels.
Anti-tumorigenic transcripts are stabilized by HEXIM1 binding
To investigate if the HEXIM1 binding shift to mRNA species upregulated by nucleotide 
stress stabilizes these RNAs, we performed an RNA stability assay where actinomycin D is 
added to halt the production of new transcripts so that degradation of steady-state transcripts 
can be observed. We performed this experiment with A771726 treatment and HEXIM1/
HEXIM2 knockdown. We observed that transcripts of CDKN1A and PTEN undergo a faster 
rate of degradation with HEXIM1/HEXIM2 knocked down (Figure 7D). Conversely, the rate 
of degradation of CCNT2 mRNA is unchanged (Figure 7D). We performed a 
complementary RNA stability experiment in the context of HEXIM1 overexpression in the 
A375-HEXIM1 cell line. With HEXIM1 overexpression, CDKN1A and PTEN transcripts 
undergo a slower rate of degradation while CCNT2 remains unchanged (Figure 7E).
Gene ontology analysis of HEXIM1-bound transcripts that were enriched in either the 
DMSO or A771726 condition revealed that apoptotic transcripts were enriched in nucleotide 
stress conditions while homeostatic cell maintenance pathways were enriched at steady state 
(Figure S7D). We propose that differential binding of HEXIM1 to certain transcripts like 
CDKN1A and PTEN stabilizes them under nucleotide stress. Other transcripts like CCNT2 
that do not experience differential binding are not affected.
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Discussion
HEXIM1 is a tumor suppressor in melanoma
Our work establishes a physiological role for HEXIM1 in melanoma in vivo, although 
further genetic validation in a mammalian system is needed. HEXIM1 was discovered as an 
upregulated gene upon treatment of cells with HMBA (Kusuhara et al., 1999). HMBA 
induces differentiation in a variety of cancer cell lines and primary human cancer cell 
cultures (Marks and Rifkind, 1989). HEXIM1 upregulation is correlated with the transition 
of cancer cells from proliferation to differentiation, and has been studied in breast cancer 
(Ketchart et al., 2013; Wittmann et al., 2003, 2005; Yeh et al., 2013) and prostate cancer 
(Mascareno et al., 2012). 7SK snRNP member LARP7 is mutated in gastric cancer (He et 
al., 2008; Mori et al., 2002). Rapidly dividing cancer cells are addicted to P-TEFb for 
proliferative gene expression, where loss of P-TEFb activity leads to growth arrest and 
apoptosis (Kryštof et al., 2012). This explains the efficacy of anti-cancer agents HMBA, 
SAHA and JQ1 that modulate HEXIM1 sequestration of PTEFb (Bartholomeeusen et al., 
2012). HEXIM1 is an important tumor suppressor that dampens excessive P-TEFb activity 
in cancer.
The ability for HEXIM1 to respond to cellular stress and participate in a transcriptional 
transition has great significance in tumorigenesis. Using DHODH inhibitors to create 
cellular stress by nucleotide starvation upregulates HEXIM1, reducing transcription 
elongation at genes associated with survival and proliferation. In addition, apoptotic genes 
upregulated by cellular stress can be stabilized by HEXIM1 binding, reinforcing the shift to 
a growth suppressive transcriptional state. Metabolic drugs such as lef that induce HEXIM1 
can transcriptionally inhibit numerous expressed genes simultaneously, targeting multiple 
pathways to halt cancer progression. Inducing the HEXIM1 stress pathway can modulate 
gene expression through transcription elongation to treat cancer.
Each cell type has an Achilles’ heal for stress, and the neural crest is sensitive to low 
nucleotides, as illustrated by patients with Miller's syndrome with DHOHD mutations and 
consequent neural crest defects (Ng et al., 2010). Other cell types may be susceptible to 
different cellular stresses, and respond in a similar manner by activating HEXIM1, reducing 
productive elongation to help the cell repair or undergo programmed cell death. Finding 
such dependencies in other cancers could lead to the development of new cancer therapies.
HEXIM1 couples nucleotide metabolism with transcriptional regulation
When cells are nucleotide starved, transcription is slowed to conserve nucleotides until 
homeostasis returns. We suggest that one mechanism in which cells conserve nucleotides is 
to repress transcription elongation, which involves upregulating HEXIM1 to sequester P-
TEFb. Increased binding of stress response transcription factor SP1 to the HEXIM1 
promoter upregulates HEXIM1 in response to nucleotide stress. Newly synthesized 
HEXIM1 sequesters P-TEFb away from gene promoters, leading to fewer phosphorylated 
RNA Pol II molecules entering productive elongation. HEXIM1 expression is tightly linked 
to nucleotide levels, with decreased nucleotides triggering an increase in HEXIM1 
expression. Cells can take advantage of the transcriptional reprieve, provided by HEXIM1 
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induced elongation inhibition, until nucleotides return to sufficient levels. HEXIM1 then 
returns to homeostatic levels, allowing transcription to return to normal. This suggests a 
feedback mechanism where cells control transcription based on the amount of mRNA 
precursors available. Cells slow their growth rate via HEXIM1 downregulation of genes 
associated with proliferation in times of starvation, conserving cellular resources until 
conditions become favorable.
There are advantages of regulating transcription elongation as a direct consequence of 
nucleotide starvation or other cellular stresses. Genes in the Drosophila embryo involved in 
key developmental pathways as well as heat shock genes are held in a paused state before 
induction (Adelman and Lis, 2012). At these genes, transcription has already been initiated 
as RNA Pol II is recruited to the promoters. RNA Pol II does not immediately transition to a 
productive elongation phase and instead, remains paused on these promoters before 
receiving signals to induce productive elongation (Chopra et al., 2009; Muse et al., 2007; 
Zeitlinger et al., 2007). This poises RNA Pol II at genes that require rapid induction 
(Adelman and Lis, 2012).
Such a system is highly beneficial to the organism as a quick and concerted response could 
limit the damage done by the stress. With nucleotide starvation, unfavorable effects might 
include DNA damage, mis-expression of mRNA and protein, and possibly bioenergetic 
issues due to the lack of ATP and GTP. An immediate repression of non-essential genes by 
halting elongation through HEXIM1 sequestration of P-TEFb will allow for stress response 
genes to be preferentially expressed with the remaining nucleotides available. Inhibiting 
transcription elongation with nucleotide starvation is a viable mechanism to ensure a quick 
response to avoid damage from cellular stress. HEXIM1 has been shown to respond to 
environmental stimuli such as UV light, signaling cascades and transcriptional perturbations 
by various inhibitors (Peterlin et al., 2012). Our study, together with others, proposes that 
HEXIM1 is a general stress sensor that responds to cellular stress by modulating gene 
expression to achieve an appropriate response.
HEXIM1 facilitates switching of gene expression programs
Our study establishes a second function of HEXIM1 of binding mRNAs to promote a gene 
expression transition. If nucleotide starvation continues at an unsustainable rate, 
programmed cell death occurs. Apoptotic genes become upregulated as a result and 
HEXIM1 can bind and stabilize these transcripts, reinforcing apoptotic gene expression. 
Other than binding 7SK to nucleate the 7SK snRNP and sequester P-TEFb, HEXIM1 can act 
as a modulator of specific RNA species under different gene expression programs.
The dual functionality of HEXIM1 might explain its importance in differentiation, where 
HEXIM1 is significantly upregulated (Marks and Rifkind, 1989). During differentiation, 
proliferation genes are downregulated and genes responsible for downstream cell fate are 
upregulated. This second function of HEXIM1 could also explain why rapidly dividing 
cancer cells undergo growth arrest and apoptosis under PTEFb inhibition by drugs. 
HEXIM1 induction inhibits P-TEFb, similar to treatment with CDK9 inhibitors, to inhibit 
cancer-associated gene expression. In addition, it stabilizes apoptotic transcripts to promote 
growth arrest and cell death. The fact that not all HEXIM1 bound transcripts are stabilized 
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by HEXIM1 suggests the presence of additional factors that are recruited to specific 
transcripts by unknown mechanisms to aid in HEXIM1-mediated RNA stabilization. 
HEXIM1 plays an important role in differentiation and tumor suppression by reducing 
productive elongation of proliferation genes and promoting the expression of cell fate or 
apoptotic genes respectively, thereby facilitating a transition from one gene expression 
program to the next.
Experimental Procedures
MiniCoopR assay
The miniCoopR vector sequence and construction was previously described (Ceol et al., 
2011). MiniCoopR vectors and Tol2 transposase mRNA were microinjected into one-cell 
zebrafish embryos generated from an incross of Tg(mitfa:BRAF(V600E)); p53−/−; mitfa−/− 
zebrafish. Rescued animals were scored weekly for the presence of visible tumors. For 
hexim deletion, the MiniCoopR vector was engineered to express Cas9 under the control of 
a mitfa promoter in order to achieve melanocyte-specific gene targeting. A gRNA efficiently 
mutating hexim was expressed off a U6 promoter while a gRNA against p53 was used as a 
negative control (Ablain et al., 2015). The two vectors were injected into one-cell stage, 
Tg(mitfa:BRAFV600E), p53−/−, mitfa−/− embryos, and tumor formation was monitored.
GRO-seq sample preparation and sequencing
GRO-seq was performed as previously described (Kim et al., 2013) with conditions 
optimized for A375 cells. One million A375 cells were treated with DMSO, 25 μM lef, or 25 
μM A771726. After 48 hr treatment, cells were washed, swelled, and lysed in lysis buffer 
with IGEPAL detergent. Cells were frozen down, nuclear run-on reaction was performed, 
and nascent RNA was isolated and sequenced.
ChIP-seq sample preparation and sequencing
ChIP-seq and ChIP-reChIP were performed as previously described (Batsché et al., 2006; 
Lee et al., 2006) with conditions optimized for A375 cells. One hundred million A375 cells 
per condition were treated with DMSO or 25 μM A771726. After 48 hr treatment, cells were 
fixed in formaldehyde and subjected to chromatin immunoprecipitation with HEXIM1, 
CDK9, POLR2A or SP1 antibodies. For reChIP experiments, eluates were diluted to reduce 
the SDS concentration before the subsequent immunoprecipitation was performed. 10 μL of 
input DNA and the entire volume of ChIP DNA samples were prepared for sequencing.
FAST-iCLIP
FAST-iCLIP was performed as described previously (Flynn et al., 2015) with some 
modifications. A375 cells were cultured and treated with DMSO or 25μM A771726 for 48 
hrs, then UV-C crosslinked. Each iCLIP experiment was normalized for total protein amount 
and partially digested with RNaseI. To isolate HEXIM-bound RNAs, HEXIM1 antibody 
conjugated to Protein A Dynabeads was incubated with RNaseI-digested lysates overnight at 
4°C on rotation. Immunoprecipi tation, washing and subsequent biochemical and library 
preparation steps were carried out for sequencing.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• HEXIM1 is a tumor suppressor in melanoma that responds to nucleotide stress.
• In nucleotide stress, HEXIM1 sequesters P-TEFb to inhibit oncogenic 
transcription.
• HEXIM1 binds and stabilizes anti-tumorigenic transcripts under nucleotide 
stress.
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Figure 1. HEXIM1 is downregulated in melanoma
(A) Gene expression plot of HEXIM1 microarray data from Talantov et al. comparing nevi/
tumor samples versus normal skin controls. The data is represented as mean ± standard 
deviation (SD).
(B) Gene expression plot of HEXIM1 microarray data from Lin et al. comparing primary 
melanoma cultures and melanoma cell lines to melanocyte culture controls (mean ± SD).
(C) Bar graph of H-scores for normal epidermis, nevi and melanoma samples (mean ± SD).
(D) HEXIM1 locus methylation plot from TCGA skin cutaneous melanoma samples, 
analyzed by MethHC (mean ± SD).
(E) Real time RT-PCR for HEXIM1 expression in A375 cells treated with 5-azacytidine for 
24 hrs normalized to GAPDH (mean of 3 replicates ± SD).
(F) Cell number of A375 cells treated with 5-azacytidine for 24-72 hrs relative to DMSO 
controls (mean of 3 replicates ± SD).
See also Figure S1.
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Figure 2. HEXIM1 activity suppresses melanoma in vivo
(A) 19 week old Tg(mitfa:BRAFV600E);p53−/−;mitfa−/− zebrafish with rescued melanocytes 
expressing tumor accelerator SETDB1, background control EGFP or HEXIM1/hexim1 in 
the MiniCoopR system.
(B) Tumor-free survival curves for EGFP, SETDB1 and HEXIM1/hexim1 MiniCoopR 
zebrafish over 25 weeks. Percentages of the total number of zebrafish that were tumor-free 
each week are plotted.
(C) Tumor-free survival curves for MiniCoopR overexpression of human HEXIM1-4A, and 
HEXIM1-4D.
(D) Tumor-free survival curves for MiniCoopR expression of p53 and hexim CRISPRs.
(E) Tumor growth rates of individual mouse xenografts with a Tet-On HEXIM1-inducible 
A375 cell line (A375-HEXIM1) over 14 days. Mice were fed either a standard diet or 
doxycycline diet (mean of 7 replicates ± SD).
See also Figure S2.
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Figure 3. Knockdown of HEXIM1 rescues nucleotide stress-associated neural crest ablation and 
melanoma suppression phenotypes
(A) Zebrafish embryos were injected with 8 ng of hexim1 or control morpholino (MO), or a 
combination of hexim1 MO and 300 pg of human HEXIM1 mRNA. Embryos were treated 
with DMSO or 6.5 μM lef at 50% epiboly and in situ hybridization was performed at 24 
hours post fertilization (hpf) for crestin or mitfa expression. Dorsal views of embryos are 
shown. Numbers indicate the number of embryos with the shown phenotype vs. the total 
number of embryos in the clutch.
(B) Embryos treated as in (A) were scored for melanocytes at 2 dpf.
(C) Four clutches of embryos were analyzed for rescue of melanocytes under the conditions 
of uninjected, hexim1 MO injected, lef treatment or hexim1 MO injected with lef treatment. 
Percentages of the number of embryos rescued in each clutch are plotted (mean ± SD).
(D) Cell number of A375 cells treated with 25 μM A771726 in combination with siRNA 
pools for GAPDH, HEXIM1 and HEXIM2 relative to DMSO controls (mean of 3 replicates 
± SD).
See also Figure S3.
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Figure 4. HEXIM1 is upregulated by pyrimidine nucleotide stress
(A) Real time RT-PCR for hexim1 expression in 24 hpf zebrafish embryos treated with lef 
normalized to gapdh (mean of 3 replicates ± SD).
(B) Real time RT-PCR for HEXIM1 expression in A375 cells treated with A771726 for 72 
hrs normalized to GAPDH (mean of 3 replicates ± SD).
(C) Western blot for hexim1 in 24 hpf zebrafish embryos treated with lef from 50% epiboly 
to 24 hpf. Numbers represent quantified pixel density of hexim1 bands relative to DMSO 
control.
(D) Western blot for HEXIM1 in A375 cells treated with A771726 for 72 hrs with quantified 
HEXIM1 pixel density relative to the DMSO control.
(E) HEXIM1-luciferase reporter assay in A375 cells treated with 10 mM HMBA, DMSO or 
25 μM A771726 for 48 hrs (mean of 2 replicates ± SD).
(F) Western blot of HEXIM1 and TATA-binding protein (TBP) in A375 cells treated with 25 
μM A771726 for 1, 24, 48 and 72 hrs with quantified HEXIM1 pixel density relative to 
DMSO control.
(G) Quantification of cell number of A375 cells treated like in (F) (mean of 3 replicates ± 
SD).
(H) Real time RT-PCR for HEXIM1 expression in A375 cells treated with 25 μM A771726, 
a cocktail of 10 μg/mL pyrimidine nucleotides (UMP and CMP) and a combination of both 
A771726 and nucleotides at 24 and 72 hrs normalized to GAPDH (mean of 3 replicates ± 
SD).
See also Figure S4 and Table S1.
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Figure 5. HEXIM1 is upregulated under nucleotide stress by SP1
(A) Real time RT-PCR for HEXIM1 expression in A375 cells treated with 25 μM A771726 
and pooled siRNAs for non-targeting siRNAs, GAPDH and SP1 at 48 hrs normalized to 
ACTB (mean of 3 replicates ± SD). This is a subset of the full screening data in Figure S5A.
(B) Cell number of A375 cells treated with 25 μM A771726 in combination with a non-
targeting siRNA pool, an SP1 or HEXIM1 siRNA pool for gene knockdown relative to 
DMSO controls (mean of 3 replicates ± SD).
(C) SP1 ChIP-seq peaks around the HEXIM1 locus in A375 cells treated with DMSO or 
A771726. Read density at the HEXIM1 locus is normalized to all called peaks and 
quantified.
See also Figure S5.
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Figure 6. HEXIM1 reduces productive elongation at tumorigenic genes by P-TEFb sequestration 
under nucleotide stress
(A) Metagene analysis of all transcribed genes ± 2 kb around transcription units for CDK9 
binding regions in DMSO- or A771726-treated (25 μM for 48 hrs) A375 cells.
(B) Metagene analysis of all transcribed genes ± 2 kb around transcription units for 
HEXIM1 binding regions in DMSO- or A771726-treated (25 μM for 48 hrs) A375 cells.
(C) ChIP-seq region plots representing the distribution of regions bound by CDK9 and 
HEXIM1 in A375 cells, treated with either DMSO or 25 μM A771726 for 48 hrs, ± 2.5 kb 
relative to all CDK9 or HEXIM1 bound sites in the DMSO-treated A375 cells.
(D) RNA Pol II traveling ratios (TR) from GRO-seq performed on 48 hr DMSO (white), 25 
μM lef (blue) or 25 μM A771762 (red) treated A375 cells (mean of 2 replicates ± SD).
(E) Metagene analysis of RNA Pol II occupancy ± 2 kb around transcription units from 
GRO-seq described in (D).
(F) Venn diagram of genes in the lef (blue) or A771762 (red) treated condition which have 
an RNA Pol II TR fold change of > 1.3.
See also Figure S6 and Table S2.
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Figure 7. HEXIM1 binds and maintains levels of anti-tumorigenic transcripts under nucleotide 
stress
(A) Pie charts summarizing the switch in mRNAs bound by HEXIM1 in response to 
nucleotide depletion.
(B) FAST-iCLIP RT-stops representing regions of HEXIM1 binding mapped to three 
representative genes.
(C) Real time RT-PCR on A375 cells treated with 25 μM A771726 and a combination of 
HEXIM1 and HEXIM2 pooled siRNAs to examine expression in three genes upregulated by 
nucleotide depletion and increasingly bound by HEXIM1 (CDKN1A, PTEN and SLC5A3), 
and two genes unchanged by nucleotide depletion and with no change in HEXIM1 binding 
(CCNT2 and DCBLD2) (mean of 3 replicates ± SD). Data is normalized to RPL11.
(D) RNA stability assay where A375 were first treated with either 25 μM A771726 or 25 μM 
A771726 in combination with siRNA knockdown of HEXIM1 and HEXIM2 for 48 hrs, 
followed by 5 μg/mL actinomycin D treatment. RNA was isolated at various time points 
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after actinomycin D treatment and relative mRNA abundance over time is plotted for 
CDKN1A, PTEN and CCNT2 (mean of 3 replicates ± SD). Data is normalized to RPL11.
(E) The RNA stability assay in (D) was repeated with the A375-HEXIM1 cell line treated 
with DMSO or 1 μg/ml doxycycline to induce HEXIM1 expression for 24 hrs (mean of 3 
replicates ± SD).
See also Figure S7 and Table S3.
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